再発性子宮頸がん患者におけるペムブロリズマブとオラパリブの併用療法

基本情報

NCT ID: NCT04641728
ステータス: 不明
試験のフェーズ: 第2相
試験タイプ: 介入
目標被験者数: 28
治験依頼者名: Saitama Medical University International Medical Center

概要

This trial is a multicenter, single-arm, phase 2 study of pembrolizumab in combination with olaparib in recurrent or metastatic cervical cancer patients who had disease progression during or after platinum-based chemotherapy.

対象疾患

Cervical Cancer

介入

Pembrolizumab(DRUG)

Olaparib(DRUG)

依頼者（Sponsor）

Cancer Institute Hospital, Japan(OTHER)

Tokyo University(OTHER)

Saitama Medical University International Medical Center(OTHER)

Aichi Cancer Center(OTHER)

National Cancer Center, Japan(OTHER_GOV)

実施施設 (1)

Saitama Medical Uiversity International Medical Center

Hidaka, Saitama, Japan